Pan et al[20] also reported a patient with advanced EBVaGC (high expression of PD-L1 and HER-2) who experienced tumor regression and 28 months of PFS with nivolumab treatment, after not responding to trastuzumab combined with chemotherapy. This evidence concerns the gene ERBB2 and neoplasm.